Intrepid Family Office Acquires HeartFlow Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: NASDAQ.COM
- Share Acquisition: Intrepid Family Office LLC purchased 110,000 shares of HeartFlow in Q1 2026, with an estimated transaction value of $2.99 million, indicating a bullish outlook towards the company.
- Position Value: By the end of the quarter, HeartFlow's stake was valued at $2.68 million, representing 2.16% of its 13F AUM, which, while outside the top five holdings, still reflects the investor's interest.
- Financial Performance: HeartFlow reported first-quarter revenue of $52.6 million, a 41% year-over-year increase, and despite a net loss of $27.4 million, this was an improvement over the previous year's loss, showcasing growth potential.
- Market Outlook: Although HeartFlow's price-to-sales ratio stands at 14, down from 18 last year, its strong sales growth and improving financials may attract more investor interest, especially given the current low stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HTFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.730
Low
35.00
Averages
38.60
High
40.00
Current: 31.730
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intrepid Family Office Acquires HeartFlow Shares
- New Investment Dynamics: According to an SEC filing dated May 15, 2026, Intrepid Family Office LLC initiated a new position in HeartFlow by acquiring 110,000 shares in Q1 2026, with an estimated transaction value of $2.99 million, indicating a bullish outlook on the company's future prospects.
- Holding Proportion Analysis: HeartFlow now accounts for 2.16% of Intrepid Family Office's 13F reportable assets, with major holdings including GLD, VTI, and PPLT, which represent 13.9%, 10.4%, and 5.8% of AUM respectively, showcasing a diversified investment portfolio.
- Financial Performance Highlights: HeartFlow reported Q1 2026 revenue of $52.6 million, reflecting a 41% year-over-year increase, and while still operating at a loss, the net loss of $27.4 million improved from $32.3 million the previous year, indicating potential for revenue growth.
- Market Outlook: Despite HeartFlow's price-to-sales ratio of 14 being lower than last year's 18, its strong sales growth and improved financial condition suggest a positive outlook for profitability, potentially attracting more institutional investors' interest.
See More
Intrepid Family Office Acquires HeartFlow Shares
- Share Acquisition: Intrepid Family Office LLC purchased 110,000 shares of HeartFlow in Q1 2026, with an estimated transaction value of $2.99 million, indicating a bullish outlook towards the company.
- Position Value: By the end of the quarter, HeartFlow's stake was valued at $2.68 million, representing 2.16% of its 13F AUM, which, while outside the top five holdings, still reflects the investor's interest.
- Financial Performance: HeartFlow reported first-quarter revenue of $52.6 million, a 41% year-over-year increase, and despite a net loss of $27.4 million, this was an improvement over the previous year's loss, showcasing growth potential.
- Market Outlook: Although HeartFlow's price-to-sales ratio stands at 14, down from 18 last year, its strong sales growth and improving financials may attract more investor interest, especially given the current low stock price.
See More
HeartFlow Reports Strong Q1 2026 Earnings with Raised Revenue Outlook
- Significant Revenue Growth: HeartFlow reported Q1 2026 revenue of $52.6 million, a 41% year-over-year increase driven by a 67% growth in global cases, showcasing the company's strong momentum in the cardiovascular imaging market and boosting investor confidence.
- Raised Full-Year Outlook: Management raised the 2026 total revenue guidance to $228 million to $232 million, while also increasing the Plaque-specific revenue outlook to $19 million to $21 million, reflecting optimistic expectations for market demand.
- Improved Gross Margin: The first quarter non-GAAP gross margin reached 81%, with management targeting a midterm goal of 85%, indicating ongoing progress in production efficiency and automation that will enhance profitability.
- New Product Launch: HeartFlow launched PCI Navigator in April, receiving positive feedback from interventional cardiologists, with plans for a phased rollout through 2026, which is expected to further drive market penetration and revenue growth.
See More
SpaceX Could Become Largest IPO in History
- IPO Valuation Outlook: SpaceX plans to go public this year with a target valuation of $1.75 trillion, which would make it the largest IPO in history, yet this implies a staggering 95 times its projected 2025 revenue of $18.5 billion, leading to mixed market expectations regarding its future growth.
- Market Competition and Profitability: While SpaceX shows potential in expanding its Starlink satellite network and launching Falcon rockets, concerns about its profitability are rising, especially under pressure from smaller competitors, prompting investors to approach with caution.
- Heartflow Growth Potential: Heartflow went public at $19 per share in August 2025 and is currently trading around $29, with a 40% revenue increase in 2025 and an expected 24%-26% growth in 2026, indicating strong growth potential in the non-invasive cardiac diagnostics sector.
- Neptune Insurance Market Positioning: Neptune Insurance focuses on flood insurance, achieving a 34% revenue increase in 2025 and expecting a 22% growth in 2026, leveraging AI and geospatial data to automate underwriting processes and meet the urgent demand for customized flood insurance solutions.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Intrepid Family Office Acquires HeartFlow Shares
- New Investment Dynamics: According to an SEC filing dated May 15, 2026, Intrepid Family Office LLC initiated a new position in HeartFlow by acquiring 110,000 shares in Q1 2026, with an estimated transaction value of $2.99 million, indicating a bullish outlook on the company's future prospects.
- Holding Proportion Analysis: HeartFlow now accounts for 2.16% of Intrepid Family Office's 13F reportable assets, with major holdings including GLD, VTI, and PPLT, which represent 13.9%, 10.4%, and 5.8% of AUM respectively, showcasing a diversified investment portfolio.
- Financial Performance Highlights: HeartFlow reported Q1 2026 revenue of $52.6 million, reflecting a 41% year-over-year increase, and while still operating at a loss, the net loss of $27.4 million improved from $32.3 million the previous year, indicating potential for revenue growth.
- Market Outlook: Despite HeartFlow's price-to-sales ratio of 14 being lower than last year's 18, its strong sales growth and improved financial condition suggest a positive outlook for profitability, potentially attracting more institutional investors' interest.
See More
Intrepid Family Office Acquires HeartFlow Shares
- Share Acquisition: Intrepid Family Office LLC purchased 110,000 shares of HeartFlow in Q1 2026, with an estimated transaction value of $2.99 million, indicating a bullish outlook towards the company.
- Position Value: By the end of the quarter, HeartFlow's stake was valued at $2.68 million, representing 2.16% of its 13F AUM, which, while outside the top five holdings, still reflects the investor's interest.
- Financial Performance: HeartFlow reported first-quarter revenue of $52.6 million, a 41% year-over-year increase, and despite a net loss of $27.4 million, this was an improvement over the previous year's loss, showcasing growth potential.
- Market Outlook: Although HeartFlow's price-to-sales ratio stands at 14, down from 18 last year, its strong sales growth and improving financials may attract more investor interest, especially given the current low stock price.
See More
HeartFlow Reports Strong Q1 2026 Earnings with Raised Revenue Outlook
- Significant Revenue Growth: HeartFlow reported Q1 2026 revenue of $52.6 million, a 41% year-over-year increase driven by a 67% growth in global cases, showcasing the company's strong momentum in the cardiovascular imaging market and boosting investor confidence.
- Raised Full-Year Outlook: Management raised the 2026 total revenue guidance to $228 million to $232 million, while also increasing the Plaque-specific revenue outlook to $19 million to $21 million, reflecting optimistic expectations for market demand.
- Improved Gross Margin: The first quarter non-GAAP gross margin reached 81%, with management targeting a midterm goal of 85%, indicating ongoing progress in production efficiency and automation that will enhance profitability.
- New Product Launch: HeartFlow launched PCI Navigator in April, receiving positive feedback from interventional cardiologists, with plans for a phased rollout through 2026, which is expected to further drive market penetration and revenue growth.
See More
SpaceX Could Become Largest IPO in History
- IPO Valuation Outlook: SpaceX plans to go public this year with a target valuation of $1.75 trillion, which would make it the largest IPO in history, yet this implies a staggering 95 times its projected 2025 revenue of $18.5 billion, leading to mixed market expectations regarding its future growth.
- Market Competition and Profitability: While SpaceX shows potential in expanding its Starlink satellite network and launching Falcon rockets, concerns about its profitability are rising, especially under pressure from smaller competitors, prompting investors to approach with caution.
- Heartflow Growth Potential: Heartflow went public at $19 per share in August 2025 and is currently trading around $29, with a 40% revenue increase in 2025 and an expected 24%-26% growth in 2026, indicating strong growth potential in the non-invasive cardiac diagnostics sector.
- Neptune Insurance Market Positioning: Neptune Insurance focuses on flood insurance, achieving a 34% revenue increase in 2025 and expecting a 22% growth in 2026, leveraging AI and geospatial data to automate underwriting processes and meet the urgent demand for customized flood insurance solutions.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
